国际眼科纵览
國際眼科縱覽
국제안과종람
OREIGN MEDICAL SCIENCES
2014年
6期
425-428
,共4页
抗血管内皮细胞生长因子%新生血管性青光眼
抗血管內皮細胞生長因子%新生血管性青光眼
항혈관내피세포생장인자%신생혈관성청광안
anti-vascular endothelial growth factor%neovascular glaucoma%treatment
新生血管性青光眼(neovascular glaucoma,NVG)是继发于眼底缺血性疾病的一类难治性青光眼.既往抗青光眼药物和手术治疗失败率较高.近几年抗血管内皮细胞生长因子(anti-vascu-lar endothelial growth factor,anti-VEGF)药物逐渐用于辅助小梁切除术、引流装置植入术、睫状体光凝/冷冻术、玻璃体切除术等综合治疗.其抗血管形成和抗成纤维细胞的特性可以有效改善视网膜缺血、迅速消除眼前段新生血管、防止术中术后前房出血和延长滤过泡寿命,明显提高了NVG手术的成功率,尤其是早期治疗的成功率.但抗VEGF在NVG治疗中的时机选择及安全性等方面还需进一步研究.
新生血管性青光眼(neovascular glaucoma,NVG)是繼髮于眼底缺血性疾病的一類難治性青光眼.既往抗青光眼藥物和手術治療失敗率較高.近幾年抗血管內皮細胞生長因子(anti-vascu-lar endothelial growth factor,anti-VEGF)藥物逐漸用于輔助小樑切除術、引流裝置植入術、睫狀體光凝/冷凍術、玻璃體切除術等綜閤治療.其抗血管形成和抗成纖維細胞的特性可以有效改善視網膜缺血、迅速消除眼前段新生血管、防止術中術後前房齣血和延長濾過泡壽命,明顯提高瞭NVG手術的成功率,尤其是早期治療的成功率.但抗VEGF在NVG治療中的時機選擇及安全性等方麵還需進一步研究.
신생혈관성청광안(neovascular glaucoma,NVG)시계발우안저결혈성질병적일류난치성청광안.기왕항청광안약물화수술치료실패솔교고.근궤년항혈관내피세포생장인자(anti-vascu-lar endothelial growth factor,anti-VEGF)약물축점용우보조소량절제술、인류장치식입술、첩상체광응/냉동술、파리체절제술등종합치료.기항혈관형성화항성섬유세포적특성가이유효개선시망막결혈、신속소제안전단신생혈관、방지술중술후전방출혈화연장려과포수명,명현제고료NVG수술적성공솔,우기시조기치료적성공솔.단항VEGF재NVG치료중적시궤선택급안전성등방면환수진일보연구.
Neovascular glaucoma (NVG) is regarded as refractory glaucoma secondary to retinal ischemia.Previous anti-glaucoma drugs and surgeries present low therapeutic effect.Recently anti-vascular endothelial growth factor (anti-VEGF) agent has been used as an adjunction for NVG comprehensive treatment,including trabeculectomy,drainage valve implantation,cyclophotocoagulation/cyclocryotherapy and vitrectomy etc.The antiangiogenic and antifibroblastic properties of anti-VEGF agents have shown great promise in reducing retinal ischemia,rapid regression of anterior segment neovascularization,preventing intra-and post-operative hyphema and improving the filtering bled,which effectively increase the operative successful rate,especially for NVG in the early stage.However,injection timing,safty and other aspects of anti-VEGF therapy in NVG treatment still need further study.
